Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Accepts Impax Pharma NDA Filing For IPX066 - Quick Facts

RELATED NEWS
Trade IPXL now with 

Impax Laboratories, Inc.'s (IPXL: Quote) branded products division, Impax Pharmaceuticals, said the U.S. Food and Drug Administration has accepted for filing the company's New Drug Application, or NDA, for IPX066 for the treatment of idiopathic Parkinson's disease submitted to the Agency on December 21, 2011. The Prescription Drug User Fee Date for a decision by the FDA is October 21, 2012.

IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.

The NDA included data from three controlled Phase III studies and two open label extensions of IPX066 in both early and advanced Parkinson's disease.

Click here to receive FREE breaking news email alerts for Impax Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The United Nations Security Council (UNSC) on Thursday declared the ongoing Ebola outbreak in West Africa "a threat to international peace and security." Notably, the declaration was made in the Council's first emergency meeting on a public health issue. The fifteen-member Council also unanimously... Oracle Corp. said Thursday after the markets closed that its first quarter profit fell slightly from last year, hurt mainly by higher income tax expenses even as revenue increased 3%. The company's quarterly earnings per share, excluding items, also came in below analysts' expectations as did its quarterly revenue. After ending the previous session mostly higher following the Federal Reserve's monetary policy announcement, stocks saw further upside during trading on Thursday. The gains on the day lifted the Dow and the S&P 500 to new record closing highs.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.